Introduction: Idiopathic intracranial hypertension (IIH) is known to elevate cardiovascular disease (CVD) risk, but the extent to which obesity and IIH-specific factors contribute to this risk is not well understood. WE aim to separate the effects of obesity from IIH-specific factors on the risk of stroke and CVD, building on previous findings that indicate a two-fold increase in cardiovascular events in women with IIH compared to BMI-matched controls.
Methods: An obesity-adjusted risk analysis was conducted using Indirect Standardization based on data from a cohort study by Adderley et al.
A Novel cold-active chitin deacetylase from Shewanella psychrophila WP2 (SpsCDA) was overexpressed in Escherichia coli BL21 and employed for deacetylation of chitin to chitosan. The produced chitosan was characterized, and its antifungal activity was investigated against Fusarium oxysporum. The purified recombinant SpsCDA appeared as a single band on SDS-PAGE at approximately 60 kDa, and its specific activity was 92 U/mg.
View Article and Find Full Text PDFBackground: In modern healthcare systems, the scope of practice for anesthesiologists is expanding within and beyond the traditional perioperative care continuum. This study was conducted to assess the knowledge and perceptions of perioperative patients of the roles of anesthesiologists as providers of healthcare services in different Palestinian hospitals. The study also assessed associations between the patients' different demographic and clinical variables and their knowledge and perceptions about the roles of anesthesiologists.
View Article and Find Full Text PDFHigh Blood Press Cardiovasc Prev
November 2024
Introduction: Hypertension and dyslipidemia are common contributors to cardiovascular disease (CVD), often occurring together. Effectively Managing both is key to reducing mortality and morbidity, but complex regimens reduce adherence.
Aim: This study investigated the comparative efficacy and safety of a three-drug regimen (TAR) containing telmisartan, amlodipine, and rosuvastatin against two-drug combinations (TA and TR) for managing hypertension and dyslipidemia.